Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Biometrical Journal. Biometrische Zeitschrift|July 12, 2007
Sample size reestimation by Bayesian predictionMing-Dauh Wang
Statistics in Medicine|July 12, 2005
Bayesian predictive approach to interim monitoring in clinical trialsAlexei Dmitrienko, Ming-Dauh Wang
Pharmaceutical Statistics|April 7, 2018
An evaluation of the trimmed mean approach in clinical trials with dropoutMing-Dauh Wang, Jiajun Liu, Geert Molenberghs, et al.
European Heart Journal|June 27, 2015
Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndromeAmit V Khera, John S Millar, Giacomo Ruotolo, et al.
Pharmacotherapy|June 11, 2016
Impact of Increased Gastric pH on the Pharmacokinetics of Evacetrapib in Healthy SubjectsDavid S Small, Jane Royalty, Ellen A Cannady, et al.
The Journal of Pharmacy and Pharmacology|June 26, 2014
Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adultsJeffrey G Suico, Ming-Dauh Wang, Stuart Friedrich, et al.
European Heart Journal|January 14, 2016
Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 studyJohn J P Kastelein, Steven E Nissen, Daniel J Rader, et al.
British Journal of Clinical Pharmacology|August 13, 2015
CYP-mediated drug-drug interactions with evacetrapib, an investigational CETP inhibitor: in vitro prediction and clinical outcomeEllen A Cannady, Jeffrey G Suico, Ming-Dauh Wang, et al.
JAMA|March 27, 2007
Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trialsSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Pharmacology Research & Perspectives|October 31, 2015
Evacetrapib: in vitro and clinical disposition, metabolism, excretion, and assessment of drug interaction potential with strong CYP3A and CYP2C8 inhibitorsEllen A Cannady, Ming-Dauh Wang, Stuart Friedrich, et al.
Pageof 2